[Effects of VPA on the Expression of Notch Signaling Pathway in Multiple Myeloma RPMI 8226 Cell Line].

Zhongguo Shi Yan Xue Ye Xue Za Zhi

Department of Hematology, Affiliated Hospital, Chengde Medical College, Chengde 067000, Hebei Province, China. E-mail:

Published: October 2016

Objective: To investigate the effects of valproic acid(VPA) on the expression of intracellular domain of Notch1 (ICN1) and Hes1 in multiple myeloma RPMI 8226 cell line.

Methods: Experiments were divided into 4 group: blank control group and groups of cells treated with VPA of different concentration (2, 4, 8 mmol/L), the cell proliferation was detected by MTT method, RT-PCR was applied to detect the mRNA expression level of ICN1 and Hes1. Western blot was used to detect the protein expression of ICN1 and Hes1.

Results: The proliferation of the RPMI 8226 cell was obviously inhibited by different concentration of VPA (2, 4, 8 mmol/L) at the same time. The same concentration of VPA was used to treat RPMI8226 cell for different time (24, 48, 72 h), the cell proliferation was obviously inhibited. Compared with control group, the mRNA and protein expression of ICN1 was significantly depressed at different concentration of VPA(2, 4, 8 mmol/L) for 48 h (P<0.05). Compared with control group, the mRNA and protein expression of Hes1 was depressed at different concentration 2, 4, 8 mmol/L)of VPA for 48 h (P<0.05).

Conclusion: VPA inhibits the proliferation of the RPMI 8226 cell in a time- and dose- dependent manner; VPA down-regulates the mRNA and protein expression level of ICN1 and Hes1 in RPMI8226 cell; thus VPA might inhibit cell proliferation possibly through the inhibition of Notch signaling pathway in multiple myeloma cells.

Download full-text PDF

Source
http://dx.doi.org/10.7534/j.issn.1009-2137.2016.05.030DOI Listing

Publication Analysis

Top Keywords

rpmi 8226
12
8226 cell
12
multiple myeloma
8
myeloma rpmi
8
icn1 hes1
8
control group
8
cell proliferation
8
protein expression
8
expression icn1
8
concentration vpa
8

Similar Publications

Peroxiredoxin 6 (PRDX6) is one of the Peroxiredoxin family members with only 1-Cys, using glutathione as the electron donor to reduce peroxides in cells. PRDX6 has been frequently studied and its expression was associated with poor prognosis in many tumors. However, the expression of PRDX6 in multiple myeloma (MM) and its relevance with MM remain unclear.

View Article and Find Full Text PDF

Reduced elastin in multiple myeloma niche promotes cell proliferation.

Exp Cell Res

December 2024

Oncogenetics Laboratory, Meir Medical Center, Tchernichovsky St 59, Kfar Saba, Israel; Faculty of Medical and Health Sciences, Tel Aviv University, PO Box 39040, Tel Aviv, Tel Aviv, Israel. Electronic address:

Multiple myeloma (MM) malignant plasma cells accumulate in the bone marrow (BM) where their interactions with the microenvironment promote disease progression and drug resistance. Previously, we have shown that bone marrow mesenchymal stem cells (BM-MSCs) (MM and normal donors- ND) derived extracellular matrix (ECM) affected MM cell lines differentially with a pro-MM effect attributed to MM-MSCs' ECM. Here we studied the composition of BM-MSC's ECM (ND versus MM) with focus on elastin (ELN).

View Article and Find Full Text PDF

The current comprehensive study showcases a meticulous synthesis of novel class of α-benzilmonoxime thiocarbohydrazide (BMOTC) derivatives, and manifesting their multifaceted potential as antibacterial, antifungal, and anticancer agents. The synthesis of target compounds was performed in three phases using literature methods. In the first step, benzilmonoxime is synthesized using benzil and hydroxyl amine hydrochloride, followed by benzilmonoxime imine using thiocarbohydrazide.

View Article and Find Full Text PDF
Article Synopsis
  • Multiple myeloma (MM) is a type of blood cancer marked by excessive production of plasma cells that release antibodies, and current research on treatments like Raddeanin A (RA) focuses mainly on solid tumors, leaving a gap in understanding its effects on MM specifically.
  • RA, derived from Anemone raddeana regel, shows promising anti-tumor effects, and this study explores how it may inhibit MM cell growth through network pharmacology and experimental methods, revealing significant interactions with the MAPK signaling pathway.
  • Experimental results demonstrate that RA effectively slows MM cell proliferation, induces apoptosis, alters mitochondrial function, and impacts the expression of key proteins involved in cell growth and survival, suggesting a powerful potential for RA as a treatment for multiple my
View Article and Find Full Text PDF

Complement-dependent cytotoxicity (CDC) is a primary mechanism-of-action of monoclonal antibody (mAb) immunotherapies used to treat haematological cancers, including rituximab and daratumumab. However, mAb efficacy may be limited by reduced bioavailability of complement C1q - which activates the complement classical pathway following interactions with mAb-opsonised target cells. C1q is secreted by phagocytes upon recruitment to sites of muscle damage to facilitate muscular repair, hence we hypothesised that muscle damaging exercise may increase C1q 'spill-over' into blood.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!